These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 9699670

  • 1. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas.
    Gu XG, Schmitt M, Hiasa A, Nagata Y, Ikeda H, Sasaki Y, Akiyoshi K, Sunamoto J, Nakamura H, Kuribayashi K, Shiku H.
    Cancer Res; 1998 Aug 01; 58(15):3385-90. PubMed ID: 9699670
    [Abstract] [Full Text] [Related]

  • 2. Development of a cancer vaccine: peptides, proteins, and DNA.
    Shiku H, Wang L, Ikuta Y, Okugawa T, Schmitt M, Gu X, Akiyoshi K, Sunamoto J, Nakamura H.
    Cancer Chemother Pharmacol; 2000 Aug 01; 46 Suppl():S77-82. PubMed ID: 10950153
    [Abstract] [Full Text] [Related]

  • 3. HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan.
    Kitano S, Kageyama S, Nagata Y, Miyahara Y, Hiasa A, Naota H, Okumura S, Imai H, Shiraishi T, Masuya M, Nishikawa M, Sunamoto J, Akiyoshi K, Kanematsu T, Scott AM, Murphy R, Hoffman EW, Old LJ, Shiku H.
    Clin Cancer Res; 2006 Dec 15; 12(24):7397-405. PubMed ID: 17189412
    [Abstract] [Full Text] [Related]

  • 4. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM.
    Cancer Res; 2001 Feb 01; 61(3):880-3. PubMed ID: 11221874
    [Abstract] [Full Text] [Related]

  • 5. Elimination of CD4+ T cells may overcome suppression of anti-HER2 immune responses in tumor-bearing hosts.
    Ishihara M, Tawara I, Wang L, Takahashi Y, Shiku H.
    Int J Oncol; 2003 May 01; 22(5):1135-9. PubMed ID: 12684682
    [Abstract] [Full Text] [Related]

  • 6. Bone marrow-derived dendritic cells incorporate and process hydrophobized polysaccharide/oncoprotein complex as antigen presenting cells.
    Wang L, Ikeda H, Ikuta Y, Schmitt M, Miyahara Y, Takahashi Y, Gu X, Nagata Y, Sasaki Y, Akiyoshi K, Sunamoto J, Nakamura H, Kuribayashi K, Shiku H.
    Int J Oncol; 1999 Apr 01; 14(4):695-701. PubMed ID: 10087316
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y.
    Clin Cancer Res; 2009 Jul 15; 15(14):4612-21. PubMed ID: 19584156
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine.
    Orlandi F, Venanzi FM, Concetti A, Yamauchi H, Tiwari S, Norton L, Wolchok JD, Houghton AN, Gregor PD.
    Clin Cancer Res; 2007 Oct 15; 13(20):6195-203. PubMed ID: 17947487
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.
    Triulzi C, Vertuani S, Curcio C, Antognoli A, Seibt J, Akusjärvi G, Wei WZ, Cavallo F, Kiessling R.
    Cancer Res; 2010 Oct 01; 70(19):7431-41. PubMed ID: 20823150
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy.
    Ikuta Y, Katayama N, Wang L, Okugawa T, Takahashi Y, Schmitt M, Gu X, Watanabe M, Akiyoshi K, Nakamura H, Kuribayashi K, Sunamoto J, Shiku H.
    Blood; 2002 May 15; 99(10):3717-24. PubMed ID: 11986228
    [Abstract] [Full Text] [Related]

  • 15. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
    Dela Cruz JS, Morrison SL, Penichet ML.
    Vaccine; 2005 Sep 15; 23(39):4793-803. PubMed ID: 15967544
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y, Morrison BJ, Burke JD, Park JM, Terabe M, Janik JE, Forni G, Berzofsky JA, Morris JC.
    Cancer Res; 2004 Nov 01; 64(21):8022-8. PubMed ID: 15520211
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
    Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN.
    Cancer Res; 2006 May 15; 66(10):5452-60. PubMed ID: 16707474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.